You may be eligible if you meet all of below:
- Are between 18 and 75 years old
- Currently taking injectable semaglutide (also known as Ozempic or Wegovy), oral semaglutide, or injectable tirzepatide (also known as Zepbound) for weight loss
- Have been on the same dose for at least 3 months
- Have a BMI of at least 23 kg/m2
There are other requirements to participate.
This clinical research study aims to find out whether the investigational study drug ALV-100 maintains your weight after stopping semaglutide/tirzepatide. The study drug is designed to be taken monthly.
Participants will receive diet and exercise counseling throughout the study period and will be compensated for study visits.
To learn more about PRESERVE and whether it may be right for you, please contact:
Shruti Sukhanandi
205-934-4980